Zacks Investment Research upgraded shares of AnaptysBio, Inc. (NASDAQ:ANAB) from a hold rating to a buy rating in a research report report published on Thursday. Zacks Investment Research currently has $34.00 price objective on the biotechnology company’s stock.

According to Zacks, “AnaptysBio, Inc. is a biotechnology company. It involved in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology primarily in the Unites states. AnaptysBio, Inc. is based in San Diego, California. “

Several other analysts have also issued reports on the stock. Credit Suisse Group upped their price target on shares of AnaptysBio from $34.00 to $38.00 and gave the company an outperform rating in a research report on Friday, August 25th. Robert W. Baird began coverage on shares of AnaptysBio in a research report on Monday, July 10th. They set an outperform rating and a $36.00 price target for the company. Six investment analysts have rated the stock with a buy rating, The company currently has an average rating of Buy and a consensus target price of $36.00.

Shares of AnaptysBio (NASDAQ:ANAB) traded up 0.92% on Thursday, reaching $31.97. The company had a trading volume of 138,904 shares. The company’s 50-day moving average is $24.43 and its 200-day moving average is $25.03. The company’s market capitalization is $650.33 million. AnaptysBio has a one year low of $15.17 and a one year high of $32.05.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.42) by $0.29. The business had revenue of $7 million for the quarter, compared to analysts’ expectations of $3.45 million. Equities research analysts predict that AnaptysBio will post ($1.96) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “AnaptysBio, Inc. (ANAB) Upgraded to Buy at Zacks Investment Research” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another website, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/09/08/anaptysbio-inc-anab-upgraded-to-buy-at-zacks-investment-research.html.

In other news, major shareholder Ventures Vii L. P. Avalon sold 37,040 shares of the stock in a transaction dated Wednesday, July 26th. The shares were sold at an average price of $24.35, for a total transaction of $901,924.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Holdings A/S Novo sold 356,300 shares of the stock in a transaction dated Monday, August 21st. The stock was sold at an average price of $21.10, for a total transaction of $7,517,930.00. Following the sale, the insider now owns 1,936,604 shares of the company’s stock, valued at $40,862,344.40. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,133,940 shares of company stock valued at $24,223,316.

Institutional investors have recently bought and sold shares of the company. Bank of America Corp DE purchased a new stake in shares of AnaptysBio during the first quarter worth about $123,000. DAFNA Capital Management LLC boosted its holdings in shares of AnaptysBio by 22.2% during the second quarter. DAFNA Capital Management LLC now owns 5,500 shares of the biotechnology company’s stock worth $132,000 after purchasing an additional 1,000 shares during the period. New York State Common Retirement Fund purchased a new stake in shares of AnaptysBio during the second quarter worth about $168,000. TIAA CREF Investment Management LLC purchased a new stake in shares of AnaptysBio during the first quarter worth about $227,000. Finally, Teachers Advisors LLC boosted its holdings in shares of AnaptysBio by 23.4% during the second quarter. Teachers Advisors LLC now owns 9,520 shares of the biotechnology company’s stock worth $228,000 after purchasing an additional 1,807 shares during the period. Institutional investors own 71.35% of the company’s stock.

AnaptysBio Company Profile

AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.

Analyst Recommendations for AnaptysBio (NASDAQ:ANAB)

Receive News & Stock Ratings for AnaptysBio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio Inc. and related stocks with our FREE daily email newsletter.